{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-172060","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2022-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.701308+00:00","generated_at":"2026-06-25T02:47:35.295366+00:00","sec_items":["1.01","2.03","5.02","5.07"],"event_type":"leadership","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CFO/COO and director Christopher Lowe resigns; June Bray appointed director; Monohon named PFO","bullets":["Christopher Lowe resigned as board member (June 8) and as CFO/COO (effective June 10); separation includes $354,750 cash severance and equity acceleration.","June Bray appointed as Class III director; receives initial option for 54,000 shares at $3.20, vesting over 3 years.","Ted Monohon, current CAO and VP Finance, designated as principal financial officer; no change in compensation.","Sublease with ICON Clinical Research for 601 Gateway Blvd, SF: term June 18, 2022 to Nov 30, 2023, optional extension; rent $16,692-$17,206/mo.","Annual meeting: elected Lowe and Senner as directors, ratified BDO as auditor, approved say-on-pay."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-172060","json":"https://secwatch.observer/filing/0001193125-22-172060.json","markdown":"https://secwatch.observer/filing/0001193125-22-172060.md","text":"https://secwatch.observer/filing/0001193125-22-172060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/d331287d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:47:35.295366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90e46225f5","claim":"Christopher Lowe resigned as Chief Financial Officer at Quince Therapeutics, Inc..","evidence_excerpt":"Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"984cba489c","claim":"Christopher Lowe resigned as Chief Operating Officer at Quince Therapeutics, Inc..","evidence_excerpt":"Mr. Lowe has also resigned from his roles as the Chief Financial Officer and Chief Operating Officer of the Company, effective as of June 10, 2022 (the “Departure Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"b3f3e09400","claim":"Christopher Lowe resigned as member of the Board of Directors at Quince Therapeutics, Inc..","evidence_excerpt":"On June 8, 2022, Christopher Lowe, the Chief Financial Officer, Chief Operating Officer and a member of the Board of Directors (the “Board”) of the Company, resigned as a member of the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"fed9f8dfe9","claim":"June Bray was appointed as Class III director at Quince Therapeutics, Inc..","evidence_excerpt":"On June 9, 2022, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed June Bray to serve as a Class III director of the Company, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}